SEC Form 4 · Rule 10b5-1 trading plans

ARS Pharmaceuticals, Inc. (SPRY)

10Trades filed under a plan
4Plan adoption dates stated
8Quarterly results prints on file
1Trades in the days before a print

In the 2025 filing year, ARS Pharmaceuticals, Inc. filed 8 Form 4 statements whose footnotes name a Rule 10b5-1 trading plan, by 5 reporting owners, covering 10 transactions filed under those plans and 287,500 shares. None carries the SEC's own AFF10B5ONE adoption flag; each of the 8 names a plan in a footnote. 8 results prints are on file in the same window, which is what makes the interval below measurable.

Trades filed under a plan in ARS Pharmaceuticals, Inc. 10

Plan adoption dates stated in ARS Pharmaceuticals, Inc. 4

Quarterly results prints on file in ARS Pharmaceuticals, Inc. 8

Trades in the days before a print in ARS Pharmaceuticals, Inc. 1

Interval to the next reported results date

For each transaction filed under a plan, the days between the transaction date and the company’s next results print. These are the dates the filings state, printed as an interval; the page draws no conclusion from them.

1Within 5 days of a print
2Within 10 days of a print
0Shortest interval, in days
0Trades with no later print on file

Adoption dates, as the filings state them

As the filings state it: “10b5-1 trading plan adopted by the Reporting Person on August 16, 2024”

Reported results dates on file

A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.

Other companies with plan records

Order the document

Every company with plan records →

Form 4 statements and their footnotes from the SEC’s EDGAR full-text search, and this company’s results dates, industry classification and state of incorporation from the SEC submissions API. The page prints the dates the filings state and the interval between them; it draws no conclusion from them.